ERBB2 and breast cancer: Active HER2-directed therapy (n = 70) was associated with increased cardiologic ED visits (OR = 4.536 [95%CI, 1.850- 11.125]).<h4>Conclusions</h4>BC subtype influenced the frequency of ED visits and patient survival.